Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-06-13
2006-06-13
Johannsen, Diana B. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S189000, C536S023200, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
07060435
ABSTRACT:
There is disclosed a method of identifying subjects having a high or low drug metabolising phenotype associated with cytochrome CYP3A5 expression, which method comprises screening genomic DNA from said subject for the presence or absence of one or more polymorphic variants in a transcription regulatory region of the sequence encoding CYP3A5. Oligonucleotide molecules for carrying out the screening are also provided.
REFERENCES:
patent: 0463395 (1992-01-01), None
patent: 0759476 (1997-02-01), None
patent: WO 00/39332 (2000-07-01), None
Jounaidi, Y et al. Sequence of the 5'-flanking region of cyp3a5: comparative anaylsis with cyp3a4 and cyp3a7. Biochem. Biophys. Res. Comm. 205(3):1741-1747 (Dec. 1994).
Aoyama, T., et al., “Cytochrome P450 hPCN3 a novel cytochrome P450IIIA gene product that is differentially expressed in adult human liver”, J.Biol. Chem. 1989 264:10388-10395.
Barwick JL., et al., “Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes” Molecular Pharmacology, 1996 50:10-16.
Boobis A.R., et al., “Dissecting the function of cytochrome P450” Br. J. Clin. Pharmacol. 1996 42:81-89.
Cholerton, S., et al., “The role of individual human cytochrome P450 in drug metabolism and clinical response” Trend Pharmac. Sci. 1992 13:434-439.
Fujii-Kuriyama, et al., “Regulation of CYP1A1 expression” FASEB J. 1002 6:706-710.
Gorski, J.C., et. al., “Regioselective biotransformation of midazolam by members of the human cytochrome P450 (CYP3A) subfamily”, Biochem. Pharmacol. 1994 9:1643-1653.
Guengerich, F.P. “Characterisation of human cytochrome P450 enzymes”, FASEB 1992 6:745-748.
Hashimoto, H., et al. “Gene structure of CYP3A4, an adult specific form of cytochrome P450 in human livers and its transcriptional control”, Eur. J. Biochem. 1993 218:585-595.
Haehner, B.D. et al. “Bimodal distribution of renal cytochrome P450 3A activity in humans”, Mol. Pharmacol., 1996 50:52-59.
Hoffman, E.C., et al. “Cloning of a factor required for activity of the Ah (dioxin) receptor”, Science, 1991 252:954-958.
Hoyo-Vadillo, C. et al. “Pharmacokinetics of nifedipine slow release tablets in Mexican subjects: further evidence for an oxidative polymorphism”, J. Clin. Pharmac. 1989 29:816-820.
Imataka, H., et al., “Cell specific translational control of transcription factor BTEB expression. The role of an upstream AUG in the 5′ untranslated region”, J. Biol. Chem. 1994 269:20668-73.
Itoh, S., et al. “Genomic organization of human fetal specific P-450IIIA7 (cytochrome P-450HFLa)- related gene (s) and interaction of transcriptional regulatory factor with its DNA element in the 5′ flanking region”, Biochimica et Biophysia Acta. 1992 1130:133-138.
Jounaidi, Y., et al., “Sequence of the 5′-flanking region of CYP3A5 comparative analysis with CYP3A4 and CYP3A7”, Biochem. Biophys. Res. Commun. 1994 205:1741-1747.
Kormori M. et al. “Fetus specific expression of a form of cytochrome P-450 in human livers”, Biochemistry 1990 29:4430-4433.
Lavrijsen K., et al. “Induction potential of antifungals containing an imidazole or triazole moiety. Miconazole and ketoconazole, but not itraconazole are able to induce hepatic drug metabolising enzymes of male rats at high doses”, Biochem. Pharmacol. 1986 35:1867-78.
Miller, G.L. “Protein determination for large numbers of samples”, Anal. Chem. 1959 31:964.
Nebert, D.W. The Ah locus: genetic differences in toxicity, Cancer, mutation and birth defects. Critical Reviews in Toxicology, 20, 153-174 (1989).
Renwick, A.G., et al., “The pharmacokinetics of oral nifedipine—a population study”, Br. J. Clin. Pharmcol. 1988 25:701-708.
Schellens, J.H.M., et al., “Lack of bimodality nifedipine plasma kinetics in a large population of healthy subjects”, Biochem. Pharmacol. 1988 37:2507-2510.
Schuetz, J., et al, “Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver”, Pharmacogenetics, 1994 4:11-20.
Shimada, T., et al, “Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver”, Proc. Natl. Acad. Sci. USA 1989 86:462-465.
Sogawa, K., et al, “Comparison of DNA-binding properties between BTEB and Sp1 (1)”. J. Biochem, 1993 114:605-9.
Watkins, P.B. “Drug metabolism by cytochromes P450 in the liver and small bowel”, Gastroenterology Clinics of North America, 1992 21:511-526.
Wrighton, S.A. et al. “Studies in the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)”. Mol. Pharmacol. 1990 38:207-213.
Rannug, A., et. al. “Genetic Polymorphism of Cytochromes P450 1A1, 2D6 and 2E1: Regulation and Toxicological Significance”, JOEM 37(1) 1995 pp. 25-36.
Jounaidi, Y., et. al. “Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?” Biochemical and Biophysical Research Communication 1996 221:466-470.
Meyer, Urs., et al. “Molecular Mechanisms of Genetic Polymorphisms of drug metabolism”, Annual Rev. Pharmacol. Toxicol, 1997, 37:269-96.
Paulussen, Aimee, et al. “Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of ploymorphic activity in humans”, Pharmacogenetics, 2000 10:415-425.
Chou, Fang-Chun, et. al. “Genetic polymorphism of cytochrome P450 3A5 in Chinese”, DMD 2001 29:1205-1209.
Kuehl, P., et al. “Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression”, Nature Genetics 2001 27:383-391.
Schuetz, E. G. et al., “Modulators and Substrates of P-glycoprotein and Cytochrome P4503A Coordinately Up-regulate these Proteins in Human Colon Carcinoma Cells”, Molecular Pharmacology 1996 49:311-318.
Yokoi, T., “Genetic Polymorphism of Drug Metabolizing Enzymes: New Mutations in CYP2D6 and CYP2A6 Genes in Japanese”, Pharmaceutical Research 1998 vol. 15 No. 4 517-524.
Gilles, P.N., et al “Single nucleotide polymorphic discrimination by an electronic dot blot assay on semiconductor microchips”, Nat. Biotech, 1999 17:365-370.
Patinen, T., et al. “Minisequencing: A Specific Tool for DNA Analysis and Diagnostics on Oligonucleotide Arrays” Genome Res. 1997 7:606-614.
Underhill, P.A., et al. “A pre-Columbian Y chromosome-specific transition and its implications for human evolutionary history” PNAS USA 1996, 93:196-200.
Medline: Accession No. 1998428039, Abstract of Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica, 112 (1) 5-14. 1998 Ref:45 Journal code: F2X. ISSN: 0015-5691.
Roskey, M. T., et al., “DNA sequencing by delayed extraction-matrix-assisted laser desorption/ionization time of flight mass spectrometry”, Proc. Natl. Acad. Sci. USA, 1996 vol. 93:4724-4729.
Shumaker, J.M. et al., “Mutation Detection by Solid Phase Primer Extension”, Human Mutation 1996 7:346-354.
Bunce, M., et al, “Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP)”, Tissue Antigens 1995 45:81-90.
Bunce, M., et al. “Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primers mixes utilizing sequence-specific primers (PCR-SSP)”, Tissue Antigens 1995 46:355-367.
Armstrong Martin
Paulussen Aimée Dymphne Catherine
Janssen Pharmaceutica
Johannsen Diana B.
LandOfFree
Genotyping cytochrome expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genotyping cytochrome expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genotyping cytochrome expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3656564